Results 101 to 110 of about 1,337,415 (292)

Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer

Frontiers in Oncology, 2014
Cancer is a traitorous archenemy that threatens our survival. Its ability to evade detection and adapt to various cancer therapies means that it is a moving target that becomes increasingly difficult to attack.
Andrew eNguyen, Louisa eHo, Yonghong eWan   +2 more
doaj   +1 more source

Immunovirological outcomes and resistance patterns at 4 years of antiretroviral therapy use in HIV-infected patients in Cambodia [PDF]

, 2011
Objectives  To report immunovirological outcomes and resistance patterns in adults treated with triple combination antiretroviral therapy (cART) for 4 years in an HIV programme of Phnom Penh, Cambodia.
Balkan, Suna, Chanchhaya, Ngeth, Ferradini, Laurent, Narom, Prak, Nerrienet, Eric, Pujades-Rodríguez, Mar, Schramm, Birgit, Som, Leakena   +7 more
core   +2 more sources

Exploration of heterogeneity and recurrence signatures in hepatocellular carcinoma

Molecular Oncology, EarlyView.
This study leveraged public datasets and integrative bioinformatic analysis to dissect malignant cell heterogeneity between relapsed and primary HCC, focusing on intercellular communication, differentiation status, metabolic activity, and transcriptomic profiles.
Wen‐Jing Wu, Jianchao Wang, Fuqing Chen, Xuefeng Wang, Bin Lan, Ruyi Fu, Hong Wen, Fangfang Chen, Wei Hong, Tian‐Yu Tang, Ying He, Gang Chen, Jianyin Zhou, Hai‐Long Piao, Di Chen, Shu‐Yong Lin   +15 more
wiley   +1 more source

Triple-combination therapy assisted with ultrasound-active gold nanoparticles and ultrasound therapy against 3D cisplatin-resistant ovarian cancer model

Ultrasonics Sonochemistry, 2022
Cancer chemotherapy suffers from drug resistance and side effects of the drugs. Combination therapies have been attracted attention to overcome these limitations of traditional cancer treatments.
Bilgi Kip, Cansu Umran Tunc, Omer Aydin
doaj  

Comparing self‐reported race and genetic ancestry for identifying potential differentially methylated sites in endometrial cancer: insights from African ancestry proportions using machine learning models

Molecular Oncology, EarlyView.
Integrating ancestry, differential methylation analysis, and machine learning, we identified robust epigenetic signature genes (ESGs) and Core‐ESGs in Black and White women with endometrial cancer. Core‐ESGs (namely APOBEC1 and PLEKHG5) methylation levels were significantly associated with survival, with tumors from high African ancestry (THA) showing ...
Huma Asif, J. Julie Kim
wiley   +1 more source

Combination treatment with doxorubicin and gamitrinib synergistically augments anticancer activity through enhanced activation of Bim [PDF]

, 2014
Background: A common approach to cancer therapy in clinical practice is the combination of several drugs to boost the anticancer activity of available drugs while suppressing their unwanted side effects.
A Hubner, AC Bellail, B Al-Lazikani, BH Kang, BH Kang, BH Kang, BH Kang, BH Kang, BL Bennett, Byoung Heon Kang, C Liedtke, Da-Eun Jo, DD Von Hoff, EA Lefrak, F Maddalena, G Kroemer, G Minotti, GV Putcha, H Puthalakath, H Yamaguchi, Hye-Kyung Park, I Leav, J Hagenbuchner, J Trepel, Jaehwa Lim, JC Wang, Ji-Eun Lee, K Lei, K Subik, M Sciacovelli, M Taipale, MC Caino, MD Siegelin, N Lopez-Royuela, Pann-Ghill Suh, PK Singal, R Ley, RJ Youle, RM Sramkoski, S Yoshida, SJ Felts, SJ Kim, Soo-Ah Park, T Hattori, T Panaretakis, TC Chou, YC Chae, YC Chae, YJ Kang   +48 more
core   +1 more source

The atypical KRASQ22K mutation directs TGF‐β response towards partial epithelial‐to‐mesenchymal transition in patient‐derived colorectal cancer tumoroids

Molecular Oncology, EarlyView.
TGF‐β has a complex role in cancer, exhibiting both tumor‐suppressive and tumor‐promoting properties. Using a series of differentiated tumoroids, derived from different stages and mutational background of colorectal cancer patients, we replicate this duality of TGF‐β in vitro. Notably, the atypical but highly aggressive KRASQ22K mutation rendered early‐
Theresia Mair, Philip König, Milena Mijović, Jessica Kalla, Anil Baskan, Loan Tran, Kristina Draganić, Pedro Morata Saldaña, Carlos Uziel Pérez Malla, Janette Pfneissl, Andreas Tiefenbacher, Julijan Kabiljo, Velina S. Atanasova, Lisa Wozelka‐Oltjan, Leonhard Müllauer, Michael Bergmann, Raheleh Sheibani‐Tezerji, Gerda Egger   +17 more
wiley   +1 more source

Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model. [PDF]

, 2013
The current first-line treatment for advanced metastatic prostate cancer, i.e. docetaxel-based therapy, is only marginally effective. The aim of the present study was to determine whether such therapy can be improved by combining docetaxel with Aneustat (
Collins, Colin C, Gao, Allen C, Gout, Peter W, Liu, Chengfei, Qu, Sifeng, Wang, Kendric, Wang, Yuwei, Wang, Yuzhuo, Wu, Rebecca, Xue, Hui   +9 more
core   +1 more source

Multidimensional OMICs reveal ARID1A orchestrated control of DNA damage, splicing, and cell cycle in normal‐like and malignant urothelial cells

Molecular Oncology, EarlyView.
Loss of the frequently mutated chromatin remodeler ARID1A, a subunit of the SWI/SNF cBAF complex, results in less open chromatin, alternative splicing, and the failure to stop cells from progressing through the cell cycle after DNA damage in bladder (cancer) cells. Created in BioRender. Epigenetic regulators, such as the SWI/SNF complex, with important
Rebecca M. Schlösser, Florian Krumbach, Eyleen Corrales, Geoffroy Andrieux, Christian Preisinger, Franziska Liss, Alexandra Golzmann, Melanie Boerries, Kerstin Becker, Ruth Knüchel, Stefan Garczyk, Bernhard Lüscher   +11 more
wiley   +1 more source

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. [PDF]

, 2012
Drug resistance presents a challenge to the treatment of cancer patients. Many studies have focused on cell-autonomous mechanisms of drug resistance. By contrast, we proposed that the tumour micro-environment confers innate resistance to therapy. Here we
Barzily-Rokni, Michal, Chapman, Paul B, Cooper, Zachary A, Davis, Ashli, Du, Jinyan, Flaherty, Keith T, Frederick, Dennie T, Golub, Todd R, Gould, Joshua, Lo, Roger S, Mongare, Margaret M, Morikawa, Teppei, Ogino, Shuji, Qian, Zhi Rong, Ribas, Antoni, Shee, Kevin, Solit, David B, Straussman, Ravid, Wargo, Jennifer A   +18 more
core   +1 more source